HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bittersweet Decision For Prestige In Little Remedies Honey Claims Review

This article was originally published in The Tan Sheet

Executive Summary

Robitussin pediatric OTCs marketer Pfizer contends in a NAD review that the brand Little Remedies is a “therapeutic effectiveness” claim because “remedy” is a “medicine, application, or treatment that relieves or cures a disease.” NAD takes a narrower view of the brand’s use of the term.

You may also be interested in...



Bayer Will Change ‘All-Day’ Vitamin Name Following Ad Board Decision

Bayer Healthcare will change the name of itsAll-Day Energy multivitamin/multimineral product under the One-A-Day line in response to recommendations from the National Advertising Review Board

CA Tries Again To Age-Restrict Workout Supplement Sales, MA On Energy Drinks

Massachusetts legislation proposes age-restricting energy drink sales and says violating parties will face fines between $50 and $250. California bill would prohibit sales of weight loss and workout products to minors, as is already proposed in New York and Massachusetts.

Bausch Shines Planned Spin-Out, Launches First US Preservative-Free OTC Antihistamine Eye Drops

Bausch + Lomb’s Alaway Preservative-Free antihistamine eye drops launch in US, The Bausch Health Companies division planned as spin-out also recently gained South Korean approval for its Lumify OTC redness reliever drops and has submissions under review in other countries.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel